Fig. 2
From: Longitudinal MRI evaluation of the efficacy of non-enhanced lung cancer brain metastases
Comparison of follow-up MR characteristics between non-enhanced and enhanced BM during treatment. Patient 5, Male, 73-year-old, adenocarcinoma of the upper lobe of right lung. The patient was treated with chemotherapy, radiotherapy and targeted therapy according to clinical guidelines. The figure shows axial T2-weighted and T1-weighted enhanced MRI images of left frontal lobe (Foci 1) enhanced and left parietal lobe (Foci 2) non-enhanced metastatic tumors. Patient 6, Female, 54-year-old, adenocarcinoma of the inferior lobe of left lung. The patient was treated with chemotherapy, radiotherapy, targeted therapy and other comprehensive treatment. The figure shows axial enhanced T1-weighted MR images of left frontal lobe (Foci 1) enhanced and left thalamus (Foci 2) non-enhanced metastatic tumors. Patient 7, Male, 33-year-old, adenocarcinoma of the right inferior lung lobe. The patient was treated with chemotherapy, radiotherapy, targeted therapy, immunotherapy and other comprehensive treatment. The figure shows axial enhanced T1-weighted MR images of left temporal lobe (Foci 1) enhanced and brain stem (Foci 2) non-enhanced metastatic tumors. Patient 8, Male, 71-year-old, adenocarcinoma of the inferior lobe of the left lung. He was treated with chemotherapy, radiotherapy, targeted therapy, immunotherapy and other comprehensive treatment. The figure shows axial enhanced T1-weighted MR images of left temporal lobe (Foci 1) enhanced and right occipital lobe (Foci 2) non-enhanced metastatic tumors. Note The follow-up time was marked in the upper right corner (Month), the MR scan sequence was marked in the lower left corner, and the yellow arrow shows the Foci 1 metastasis and the red arrow shows the Foci 2 metastasis.
